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The insulin-like growth factors (IGF) play an important role in fetal and postnatal development. Recently, 
the nucleotide sequences of the cDNAs encoding IGF-I and IGF-II and part of the human IGF genes were 
reported. In this communication we describe two distinct IGF-II cDNAs isolated from a human adult liver 
and a human hepatoma cDNA library, respectively. Using these two cDNAs, we have established that the 
human IGF-II gene contains at least 7 exons. Two different IGF-II promoters have been identified, 19 kilo- 
bases (kb) apart, which are active in a development-specific manner. The promoter, active in the adult stage, 
is located only 1.4 kb downstream from the insulin gene. 
Insulin-like growth factor II; Somatomedin; Eukaryotic promoter; Development; (Human gene) 
1. INTRODUCTION 
The somatomedins or insulin-like growth factors 
(IGF) play an important role in fetal and postnatal 
growth and development [1,2]. Two major human 
IGFs have been fully characterized; IGF-I is a 
basic peptide of 70 amino acids, while IGF-I I  is a 
neutral peptide containing 67 residues [3,4]. The 
nucleotide sequences of cDNAs encoding IGF-I 
and IGF-I I  and part of the human IGF genes have 
been reported [5-14]. The cDNA sequences 
predict that both IGFs are synthesized as larger 
precursor molecules which undergo extensive pro- 
cessing. 
Here, we describe the characterization of two 
distinct IGF-I I  cDNAS isolated from a human 
adult liver and a human hepatoma cDNA library, 
respectively. These cDNAs, differing from each 
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other in their 5'-noncoding regions, have been 
used to determine the gene structure. We have 
identified two different IGF-I I  promoters, 19 kb 
apart, which are active in a development-specific 
manner. 
2. MATERIALS AND METHODS 
2.1. Libraries 
A cDNA library from the human hepatoma cell 
line HepG2 was kindly provided by Drs P. Berg 
and M. McPhaul (Stanford, USA). It was con- 
structed as described in [15] and has a complexity 
of 2 x 106 independent clones. Two non-amplified 
human genomic cosmid libraries were constructed 
from human placenta DNA and from GM 1416, 
48XXXX cell line DNA [11]. 
2.2. Restriction mapping, nucleotide sequence 
analysis and primer extension 
The isolated cDNAs and cosmid clones were 
characterized by restriction enzyme analysis and 
Southern blot hybridization. Using [ce-32p]dCTP- 
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labeled cDNAs as probes, restriction maps were 
constructed. For nucleotide sequence analysis the 
procedure of Maxam and Gilbert [16] was used. 
Primer extension was performed as in [17]. 
2.3. DNA probes 
The cDNA probes isolated from the plasmid 
plGF- I I  [8] contain the coding sequences of the 
IGF-I I  precursor, preceded by a 5'-nontranslated 
region of 526 bp. Genomic probes were isolated 
from the cosmid clones and contain sequences 
specific for several exons as indicated in the legend 
to fig.3. Double-stranded DNA probes were la- 
beled by nick translation with [~-3zP]dCTP to a 
specific activity of 10 s cpm//~g. 
2.4. Northern blotting 
Poly(A) + RNA was isolated from fetal and adult 
liver by the guanidinium thiocyanate/CsC1 method 
[18] and one round of oligo(dT)-cellulose 
chromatography [19]. Glyoxalated RNAs [20] 
were size-fractionated on 0.8% agarose gels (10/~g 
per lane), transferred onto nylon hybridization 
membranes (Hybond N, Amersham, England) and 
hybridized to different 3zP-labeled probes. After 
hybridization the membranes were washed to a 
final stringency of 0.1 × SSC, 1% SDS, at 65°C 
for 30 rain. 
3. RESULTS AND DISCUSSION 
From an adult human liver cDNA library several 
IGF-II-specific cDNAs have been isolated, but 
none contains the 5'-terminus of IGF-I I  mRNA 
[8]. Localization of the cDNA sequences on 
cosmid clones showed that the IGF-I I  gene con- 
tains at least two 5'-noncoding exons and three 
coding exons [11]. Further analysis revealed that 
one of these cDNAs contains sequences derived 
from a third 5'-noncoding exon. A schematic 
representation f this cDNA and the nucleotide se- 
quence of its 5'-terminus are shown in fig.lA. 
These results imply that IGF-I I  mRNA from adult 
liver is transcribed from six exons, viz. three 
5'-nontranslated exons (exons 1-3) and three ex- 
ons coding for the IGF-I1 precursor (exons 5-7). 
From the human hepatoma cell line HepG2 we 
isolated one IGF-II-specific lone. Analysis of this 
cDNA revealed that it consists of the three coding 
exons (exons 5-7) preceded at the 5'-end by a 
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Fig. 1. Schematic representation a d 5'-nucleotide s quences of IGF-1I cDNAs isolated from a human adult liver library 
(A) and a human hepatoma cell line HepG2 library (B). The nucleotide sequences of exons 2-7 have been published 
elsewhere [7,8,11]. The regions encoding the mature peptide (B,C,A,D), those coding for the signal peptide (pre) and 
the C-terminal peptide (E) as well as 5'- and 3'-nontranslated sequences are indicated. 
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nucleotide sequence, diverging from the splice site 
onwards, which has not been detected before in 
other human cDNAs (fig.lB). The sequence is 
homologous to a rat liver cell line (BRL3A) cDNA 
sequence determined by Dull et al. [7] and identical 
to a sequence localized on the human 
chromosome. This 5'-noncoding sequence is 
designated exon 4. 
Employing the two above-mentioned IGF-II 
cDNAs as probes we determined the precise posi- 
tions of the IGF-II specific sequences on 
chromosomal cosmid clones. The complete map of 
the IGF-II gene is shown in fig.2. The human IGF- 
II gene contains seven exons and spans 28 kb of 
chromosomal DNA. Four 5' -noncoding exons (ex- 
ons 1-4) are followed by three exons (exons 5-7) 
coding for the IGF-II precursor. The 5' -noncoding 
exons are used in alternative transcripts. Adult 
liver mRNA consists of exons 1-3, 5-7, while 
HepG2 mRNA contains exons 4-7, suggesting the 
presence of two different promoters. A striking 
feature of the IGF-II gene is its location close to 
the insulin gene. Bell and co-workers [10] 
established that the genes for insulin and IGF-II 
are contiguous with a maximal distance of 12.6 kb. 
Our data further reduce this distance to only 
1.4 kb (fig.2). 
Since the two characterized cDNAs contain dif- 
ferent 5'-nontranslated sequences, while only a 
single IGF-II gene is present, we established at 
which stage in development the two corresponding 
mRNAs are expressed. Poly(A) + RNA was 
isolated from fetal and adult human liver. Nor- 
thern blots of poly(A) + RNA were hybridized with 
three different 32p-labeled probes. Hybridization 
with an IGF-II probe containing exon 6 to RNA 
blots containing 10/zg poly(A) + RNA from fetal 
and adult human liver revealed strong expression 
of a 6.0 kb mRNA in fetal liver, while in adult liver 
mRNA a weak band of 5.3 kb was detected (fig.3, 
lanes 3,4). This indicates that the IGF-I! gene is 
predominantly expressed in fetal tissue. To 
establish the expression of the different 
5'-noncoding exons, poly(A) + RNA blots were 
hybridized with fragments containing exon 1 and 
exon 4 sequences, respectively. The probe contain- 
ing exon 1 sequences hybridized to the 5.3 kb band 
in adult mRNA and not to the 6.0 kb band in fetal 
liver (fig.3, lanes 5,6) indicating that exon 1 se- 
quences are only present in adult mRNA and not 
in fetal mRNA. On the other hand, the exon 4 
probe hybridized only to the 6.0 kb band in fetal 
mRNA (fig.3, lanes 1,2), suggesting that this exon 
is only expressed in fetal tissue. 
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----7/ / , COS ins-igf2 
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Fig.2. Schematic representation of the insulin and IGF-II gene region. Two partially overlapping cosmid clones were 
used to characterize the IGF-1I gene structure: cos igf2 contains exons 2-7 of the IGF-II gene [Ill and cos ins-igf2, 
isolated from the GM1416 cosmid library, encompasses the seven exons of the IGF-II gene as well as the three exons 
of the insulin gene. The positions of the IGF-II exons were determined by restriction enzyme and nucleotide sequence 
analysis. The structure and sequence of the insulin gene have been reported previously by Bell et al. [26]. A restriction 
map of the IGF-II and insulin gene region for the restriction enzymes HindIII (H) and EcoRI (E) is shown. 
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Fig.3. Northern blots of fetal and adult human liver RNA. Poly(A) ÷ RNA was isolated from human fetal and adult 
liver (10/zg per lane). Lanes: 1,2, hybridization with an 852 bp genomic fragment of exon 4 (nucleotides 164-915 in 
[7]); 3,4, hybridization with an 825 bp genomic fragment containing sequences of exon 6, coding for mature peptide 
and the initial sequences of the E-domain; 5,6, hybridization with a 945 bp genomic fragment (nucleotides 503-1447, 
fig.4B) containing part of the exon 1 sequence as well as upstream sequences. 
To determine the precise positions of initiation 
of transcription, primer extension experiments 
were performed with poly(A) ÷ RNA from fetal 
and adult liver. A primer of 20 nucleotides (com- 
plementary to nucleotides 272-291, fig.4A) 
hybridized to fetal mRNA, resulting in an elonga- 
tion product of about 100 nucleotides (not shown). 
Nucleotide sequence analysis of the primer exten- 
sion product revealed that initiation of transcrip- 
tion in the fetal stage occurs at position 186 
(fig.4A). An analogous experiment with adult 
poly(A) ÷ RNA and an exon 1 primer (complemen- 
tary to nucleotides 1469-1488, fig.4B) yielded ex- 
tension products of 90-95 nucleotides, suggesting 
that initiation of transcription takes place at 
nucleotides 1394-1397 (fig.4B). Due to the low 
abundance of IGF-I I  mRNA in adult liver, 
nucleotide sequence analysis of the primer exten- 
sion product was not feasible. 
The identification of two sites of initiation of 
transcription suggests the presence of two indepen- 
dent promoters. In order to investigate the struc- 
ture of these promoters we have determined the 
genomic nucleotide sequences preceding the two 
start sites of transcription. For the fetal promoter, 
the region upstream of exon 4 was sequenced 
(1-185, fig.4A). In this region a TATA box is 
found at positions -25  to - 19 with respect o the 
site of initiation of transcription, while a CAAT 
box ( -82  to -86)  and an Spl recognition se- 
quence ( -  113 to - 104) are also present. These se- 
quences are characteristic elements of most 
eukaryotic promoters [21]. 
For characterization of the adult promoter we 
have determined the nucleotide sequence of the 
1.4 kb intergenic region between the insulin gene 
and exon 1 of the IGF-I I  gene (fig.4B). This region 
exhibits a number of remarkable features. Firstly, 
the region upstream of exon 1 does not contain 
TATA and CAAT boxes, but an Spl recognition 
site (nucleotides 1344-1353) is present. Further, a 
GC-rich region of about 80 nucleotides precedes 
the putative site of initiation of transcription. 
These features have also been established for a 
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Fig.4. Nucleotide sequences of human chromosomal DNA containing the fetal and adult IGF-II promoters. (A) 
Genomic nucleotide sequence containing part of exon 4 and its 5'-flanking region. Nucleotides 258-360 were also 
determined by Dull et al. [7]. This region contains the IGF-II promoter active in human fetal liver. The TATA sequence 
is boxed, while a CAAT-box ( - - - )  and an Spl recognition sequence (:--==) are indicated. The site of transcription 
initiation is shown (A). (B) Nucleotide sequence of the intergenic region between the human insulin and IGF-II genes 
containing the IGF-II promoter active in human adult liver. Nucleotide 1 is the first nucleotide downstream of the 
polyadenylation site of the insulin, gene [25]. The site of initiation of transcription determined by primer extension is 
indicated (A). The repeated CAGCCC sequence is underlined as well as a 66 bp inverted repetition. An Spl recognition 
sequence is shown (--:=:). 
number of  so-called housekeeping enes, which are 
expressed at low levels in a variety of  tissues [22]. 
Secondly, the intergenic region contains a number 
of  direct and inverted repeats. Besides several 
CAGCCC repeats there is an almost perfect 66 bp 
inverted repeat at positions 521-586 and 
1155-1221 (fig.4B). These repeats might be in- 
volved in regulation of  expression by interaction 
with regulatory proteins. 
Since the nucleotide sequences upstream of  exon 
1 do not contain typical eukaryotic promoter 
elements we have investigated whether this region 
exhibits promoter activity. A 267 bp fragment 
(nucleotides 1186-1452) of  the intergenic region 
was inserted in front of  a promoter-defective 
neomycin-resistance g ne. A mouse hepatoma cell 
line [23] was transfected with this eukaryotic ex- 
pression plasmid and the transfected cells were 
tested for expression of  the neomycin-resistance 
gene. Preliminary results show that the 267 bp 
fragment acts as a strong promoter (not shown). 
This confirms the notion that the region upstream 
263 
Volume 214, number 2 FEBS LETTERS April 1987 
from exon 1 is involved in expression of the IGF-I I  
gene in adult liver. Further analysis of the pro- 
moter regions of the IGF-I I  gene is in progress. 
Tissue-specific expression of the IGF-I I  gene has 
been reported previously [24]. The present data in- 
dicate that the IGF-I I  gene can also be expressed in 
a development-dependent wayusing two different 
promoters. Since the number of known genes with 
development-specific expression is still very limited 
[25], more detailed investigation of the human 
IGF-I I  gene with its remarkable regulation of ex- 
pression is imperative. This might lead to the iden- 
tification of development-specific transcription 
factors and the elucidation of various processes in- 
volved in development and differentiation. 
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